COBRE Phase II

Under the leadership of Edward A. Kolb, M.D., The Delaware Comprehensive Sickle Cell Research Center of Biomedical Research Excellence (DE SCD COBRE) submitted a competitive renewal application to continue capacity-building and innovative research with a thematic focus on translational, clinical and psychosocial research in sickle cell disease.  On August 6, 2021, we received an award of $10.5 million for another 5 years for the Program from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) under Award Number 2P20GM109021.

The DE SCD COBRE Phase II presents a new mentoring model, a new pilot funding program, a new Clinical Research and Data Informatics Core and four new research project investigators. Each of these new additions builds on success in Phase 1 and is responsive to areas of strength and growth. Additionally, we will develop a multidisciplinary and systematic approach to study the influence of stigma and racism within communities and the healthcare system on the efficacy of both routine health maintenance and targeted interventions in patients with SCD.